Condition: Myotonic Dystrophy 1 · Sponsor: PepGen Inc
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
This description comes directly from the study's public registry record.
PepGen Patient Advocacy · 781-797-0979 · clinicaltrials@pepgen.com
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
| Ottawa Hospital Research Institute | Ottawa, Ontario, Canada | Recruiting |
| CIUSSS du Saguenay-Lac-Saint-Jean | Saguenay, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07220603